This trial is active, not recruiting.

Condition pancreatic cancer
Sponsor National Taiwan University Hospital
Start date March 2010
End date March 2011
Trial size 300 participants
Trial identifier NCT01127815, 201004002R


Pancreatic cancer is a disease with an extremely poor prognosis. Such poor results are largely due to a high incidence of local or peritoneal recurrence even after curative R0 resection. If occult microscopic metastasis or residual cancer could be predicted correctly and identify the high risk of peritoneal recurrence, we may have chance to treat these patients by different multimodal locoregional or adjuvant therapy to improve the treatment outcome.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control

Eligibility Criteria

Male or female participants from 20 years up to 90 years old.

Inclusion Criteria: - Patients with pancreatic cancers, other non-ductal pancreatic cancers , and benign pancreatic tumors (as negative control population) operated in Surgical Department after IRB proof and receiving patients' informed consent. Exclusion Criteria: - Pregnant women

Additional Information

Official title Identify the Clinical Significance and Potential Implications of PWC in Patients With Pancreatic Cancer
Principal investigator Ching-Yao Yang, M.D.
Description The purpose of this study has three specific aims: (1) to determine the relationship between peritoneal washing cytology (PWC) results and clinicopathologic parameters of pancreatic cancers, (2) to identify the predictive value of PWC and postoperative drainage cytology on the peritoneal recurrence or outcomes, (3) to dissect the molecular mechanism of peritoneal recurrence, especially on the PWC-inducing peritoneal seeding process.
Trial information was received from ClinicalTrials.gov and was last updated in May 2010.
Information provided to ClinicalTrials.gov by National Taiwan University Hospital.